Shifting Paradigm: A New Era in Treating Spinal Muscular Atrophy

Watch these dynamic presentations and roundtables from multidisciplinary experts to learn how you can improve screening, diagnosis, and management of spinal muscular atrophy in pediatric patients.
Vanessa Battista, MS, RN, CPNP
Nancy L. Kuntz, MD

ClinicalThought

Even with treatments now available for SMA, clinicians must be mindful that we are still giving the diagnosis of a lifelong chronic illness requiring support for both child and family. Here, I share my perspective on how best to support, counsel, and educate families during this challenging period.

Vanessa Battista, MS, RN, CPNP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Nurse Practitioners: 0.25 NAPNAP CE contact hours Released: October 5, 2020 Expired: October 4, 2021

With 3 FDA-approved agents now available for SMA, here’s my summary of the most clinically important information to help you educate families and assist them in making decisions about treatment.

Nancy L. Kuntz, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Nurse Practitioners: 0.25 NAPNAP CE contact hours Released: October 23, 2020 Expired: October 22, 2021
Provided by Clinical Care Options, in collaboration with the National Association of Pediatric Nurse Practitioners

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

 

5 Hanover Square, Suite 1401
New York, NY 10004
Phone: 877-662-7627
Email: info@napnap.org

Supported by educational grants from
Biogen
Genentech, a member of the Roche Group

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue